HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • S. Fidler, Imperial College London
  • ,
  • S. Lewin, University of Melbourne
  • ,
  • S. Deeks, Zuckerberg San Francisco General Hospital University of California
  • ,
  • O. S. Sogaard
  • ,
  • L. Vanderkerckhove, Ghent University
  • ,
  • S. Collins, HIV i-BASE
  • ,
  • D. Kelly, Patient Advocacy Alliance, Manchester
  • ,
  • J. Singh, Centre for the AIDS Programme of Research in South Africa
  • ,
  • M. Caskey, Rockefeller University
  • ,
  • J. Frater, University of Oxford

This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.

OriginalsprogEngelsk
Artikelnummer100025
TidsskriftJournal of virus eradication
Vol/bind7
Nummer1
Antal sider4
ISSN2055-6640
DOI
StatusUdgivet - mar. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 207282969